Is tumour radiosensitization by misonidazole a general phenomenon?

Area of Science:

• Radiation Oncology
• Cancer Biology
• Pharmacology

Background:

• Hypoxic cells in tumors are resistant to radiation therapy.
• Misonidazole (MISO) is a hypoxic cell radiosensitizer.
• Assessing tumor radiosensitization is key to improving cancer treatment outcomes.

Purpose of the Study:

• To evaluate the radiosensitizing effect of misonidazole (MISO) on various mouse tumor sub-lines.
• To determine the presence and extent of naturally occurring hypoxic cells in different tumors.
• To compare the radiosensitizing and cytotoxic effects of MISO.

Main Methods:

• Regrowth delay assay after irradiation and MISO administration.
• Assessment of MISO efficacy under ambient and clamped (acutely hypoxic) conditions.
• Calculation of hypoxic fractions using regrowth-delay data.

Main Results:

• 13 out of 14 mouse tumor sub-lines showed significant radiosensitization with MISO, indicating naturally hypoxic cells.
• A slow-growing sarcoma was not sensitized under ambient conditions but showed sensitization when acutely hypoxic.
• Hypoxic fractions varied widely, from <0.1% to ≥30%, depending on the tumor and estimation method.

Conclusions:

• Misonidazole effectively radiosensitizes naturally hypoxic tumor cells across diverse sub-lines.
• Tumor growth rate and histology influence the presence of hypoxic cells.
• Regrowth delay data provide valuable insights into tumor hypoxic fractions and MISO efficacy.